vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2024.3.TX.1vmireaviz-1056Research ArticleДонорство и трансплантация органов и тканейOrgan and tissue donation and transplantationРоль иммунотолерантности в иммуносупрессивной терапии после трансплантации печениThe role of immunotolerance in immunosuppressive therapy after liver transplantationhttps://orcid.org/0000-0002-0241-1298АносоваЕ. Ю.AnosovaE. Yu.

Аносова Екатерина Юрьевна - Врач – клинический ординатор центра трансплантации печени Вклад автора: подготовка концепции работы.

Большая Сухаревская пл., д. 3, г. Москва, 129090;ул. Островитянова д. 1, г. Москва, 117997

Ekaterina Yu. Anosova - Clinical resident of the liver transplantation Center Author's contribution: preparation of the concept of work.

3, Bolshaya Sukharevskaya Square, Moscow, 129090;1, Ostrovityanova str., Moscow, 117997

anosova.kate@gmail.comhttps://orcid.org/0000-0001-9002-1101ПолудкинИ. А.PoludkinI. A.

Полудкин Иван Алексеевич - Студент 5 курса лечебного факультета Вклад автора: написание текста работы.

ул. Высоковольтная, д. 9, г. Рязань, 390026

Ivan A. Poludkin - 5th year student of the Faculty of Medicine Author's contribution: writing the text of the work.

Vysokovoltnaya str., 9, Ryazan, 390026

https://orcid.org/0000-0001-5723-4818КазымовБ. И.KazymovB. I.

Казымов Бахтияр Исметович - Врач-хирург, научный сотрудник центра трансплантации печени; ассистент кафедры хирургических болезней Вклад автора: подготовка выводов и заключения.

Большая Сухаревская пл., д. 3, г. Москва, 129090;ул. Краснобогатырская, д. 2, стр. 2, г. Москва, 107564

Bakhtiyar I. Kazymov - Surgeon, researcher at the Liver Transplantation Center; Assistant of the Department of Surgical Diseases Author's contribution: preparation of conclusions.

3, Bolshaya Sukharevskaya Square, Moscow, 129090;2, Krasnobogatyrskaya str., p. 2, Moscow, 107564

Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияN.V. Sklifosovsky Research Institute of Emergency Medicine; N.I. Pirogov Russian National Research Medical UniversityRussian FederationРязанский государственный медицинский университет имени академика И.П. ПавловаРоссияRyazan State Medical University named after Academician I.P. PavlovRussian FederationНаучно-исследовательский институт скорой помощи им. Н.В. Склифосовского; Московский медицинский университет «Реавиз»РоссияN.V. Sklifosovsky Research Institute of Emergency Medicine; Moscow Medical University «Reaviz»Russian Federation202412072024143111120Copyright © Аносова Е.Ю., Полудкин И.А., Казымов Б.И., 20242024Аносова Е.Ю., Полудкин И.А., Казымов Б.И.Anosova E.Y., Poludkin I.A., Kazymov B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/1056

Актуальность. Некоторые достижения, связанные с трансплантацией печени в области инфекционных осложнений, лечения отторжения и хирургической тактики во многом способствовали улучшению выживаемости пациентов. Тем не менее, огромный прогресс, достигнутый в области трансплантологии, в основном связан с появлением безопасных и эффективных иммуносупрессивных средств. Но осложнения от иммуносупрессивных средств все еще являются значимой проблемой и возможность отказаться от иммуносупрессантов вовсе или значительно снизить дозу поможет решить ее. Цель: представить обзор литературы и разобрать основные аспекты иммунотолерантности в иммуносупрессивной терапии после трансплантации печени. Материалы и методы. Использована зарубежная и российская литература на тему иммунотолерантности и иммуносупрессивной терапии. Поиск литературных данных проводился в международных базах данных (PubMed/MedLine, ResearchGate), а также в научной электронной библиотеке России (eLIBRARY.RU) за период 2019–2024 гг. Заключение. Несомненно, отказ от иммуносупрессивной терапии является блестящей перспективой для реципиентов не только печени, но и других донорских органов, поэтому с будущим развитием междисциплинарных и многофакторных исследований, применение различных новых экспериментальных методов может предоставить больше возможностей и теоретического руководства для поиска пути достижения толерантности при трансплантации печени.

Relevance. Some achievements related to liver transplantation in the field of infectious complications, rejection treatment and surgical tactics have also contributed to improving patient survival. Nevertheless, it is true that the huge progress made in the field of transplantation is mainly due to the emergence of safe and effective immunosuppressive drugs. But complications from immunosuppressive drugs are still a significant problem and the ability to give up immunosuppressants altogether or significantly reduce the dose will help solve it. Aim: to present a review of the literature and to analyze the main aspects of immunotolerance in immunosuppressive therapy after liver transplantation. Materials and methods: Foreign and Russian literature on the topic of immunotolerance and immunosuppressive therapy was used. The search for literary data was carried out in international databases (PubMed/MedLine, ResearchGate), as well as in the scientific electronic library of Russia (eLIBRARY.RU ) for the period 2019– 2024. Conclusion. Undoubtedly, the rejection of immunosuppressive therapy is a brilliant prospect for recipients not only of the liver, but also of other donor organs, therefore, with the future development of interdisciplinary and multifactorial research, the use of various new experimental methods may provide more opportunities and theoretical guidance to find a way to achieve tolerance in liver transplantation.

иммунотолерантностьиммуносупрессивная терапиятрансплантация печениотторжение трансплантатаосложнения трансплантации печенииммунный ответimmunotoleranceimmunosuppressive therapyliver transplantationtransplant rejectioncomplications of liver transplantationimmune responseReferencesZhou AW, Jin J, Liu Y. Cellular strategies to induce immune tolerance after liver transplantation: Clinical perspectives. World J Gastroenterol. 2024 Apr 7;30(13):1791-1800. https://doi.org/10.3748/wjg.v30.i13.1791. PMID: 38659486; PMCID: PMC11036497.Zhou AW, Jin J, Liu Y. Cellular strategies to induce immune tolerance after liver transplantation: Clinical perspectives. World J Gastroenterol. 2024 Apr 7;30(13):1791-1800. https://doi.org/10.3748/wjg.v30.i13.1791. PMID: 38659486; PMCID: PMC11036497.Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013 Jul;10:434–440.Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013 Jul;10:434–440.Meirelles Júnior R.F. Salvalaggio P. Rezende MB de et al. Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015;13:149–152.Meirelles Júnior R.F. Salvalaggio P. Rezende MB de et al. Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015;13:149–152.Lee JH, Lee SK, Lee HJ, Seo JM, Joh JW, Kim SJ, Kwon CH, Choe YH. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J. 2009 Dec 31;50(6):784-8. https://doi.org/10.3349/ymj.2009.50.6.784. Epub 2009 Dec 18. PMID: 20046418; PMCID: PMC2796404.Lee JH, Lee SK, Lee HJ, Seo JM, Joh JW, Kim SJ, Kwon CH, Choe YH. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J. 2009 Dec 31;50(6):784-8. https://doi.org/10.3349/ymj.2009.50.6.784. Epub 2009 Dec 18. PMID: 20046418; PMCID: PMC2796404.Lin NC, Wang HK, Yeh YC, Liu CP, Loong CC, Tsai HL, Chen CY, Chin T, Liu C. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients. J Pediatr Surg. 2015 Dec;50(12):2128-33. https://doi.org/10.1016/j.jpedsurg.2015.08.043. Epub 2015 Aug 28. PMID: 26377868.Lin NC, Wang HK, Yeh YC, Liu CP, Loong CC, Tsai HL, Chen CY, Chin T, Liu C. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients. J Pediatr Surg. 2015 Dec;50(12):2128-33. https://doi.org/10.1016/j.jpedsurg.2015.08.043. Epub 2015 Aug 28. PMID: 26377868.Wozniak L.J., Venick R.S., Naini B.V., Scapa J., Hickey M.J., Rossetti M., et al. Operational Tolerance Is Not Always Permanent: A 10-Year Prospective Study in Pediatric Liver Transplant Recipients, Liver Transplantation, Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022.Wozniak L.J., Venick R.S., Naini B.V., Scapa J., Hickey M.J., Rossetti M., et al. Operational Tolerance Is Not Always Permanent: A 10-Year Prospective Study in Pediatric Liver Transplant Recipients, Liver Transplantation, Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022.Pérez-Escobar J, Jimenez JV, Rodríguez-Aguilar EF, Servín-Rojas M, Ruiz-Manriquez J, Safar-Boueri L, Carrillo-Maravilla E, Navasa M, García-Juárez I. Immunotolerance in liver transplantation: a primer for the clinician. Ann Hepatol. 2023 Jan-Feb;28(1):100760. https://doi.org/10.1016/j.aohep.2022.100760. Epub 2022 Sep 28. PMID: 36179797.Pérez-Escobar J, Jimenez JV, Rodríguez-Aguilar EF, Servín-Rojas M, Ruiz-Manriquez J, Safar-Boueri L, Carrillo-Maravilla E, Navasa M, GarcíaJuárez I. Immunotolerance in liver transplantation: a primer for the clinician. Ann Hepatol. 2023 Jan-Feb;28(1):100760. https://doi.org/10.1016/j.aohep.2022.100760. Epub 2022 Sep 28. PMID: 36179797.Montano-Loza AJ, Rodríguez-Pera'lvarez ML, Pageaux GP, Sanchez-Fueyo A, Feng S. Liver transplantation immunology: immunosuppression, rejection, and immunomodulation. J Hepatol. 2023 Jun;78:1199–1215.Montano-Loza AJ, Rodríguez-Pera'lvarez ML, Pageaux GP, San- chez-Fueyo A, Feng S. Liver transplantation immunology: immuno- suppression, rejection, and immunomodulation. J Hepatol. 2023 Jun;78:1199–1215.Nakajima I, Tsukimura T, Ono T, Shiga T, Shitara H, Togawa T, Sakuraba H, Miyaoka Y. In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells. Cell Transplant. 2023 Jan-Dec;32:9636897231173734. https://doi.org/10.1177/09636897231173734. PMID: 37183961; PMCID: PMC10186575.Nakajima I, Tsukimura T, Ono T, Shiga T, Shitara H, Togawa T, Sakuraba H, Miyaoka Y. In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells. Cell Transplant. 2023 Jan-Dec;32:9636897231173734. https://doi.org/10.1177/09636897231173734. PMID: 37183961; PMCID: PMC10186575.Safinia, Niloufar & Grageda, Nathali & Scottà, Cristiano & Thirkell, Sarah & Fry, Laura & Vaikunthanathan, Trishan & Lechler, Robert & Lombardi, Giovanna. (2018). Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Frontiers in Immunology. 9. 10.3389/fimmu.2018.00354.Safinia, Niloufar & Grageda, Nathali & Scottà, Cristiano & Thirkell, Sarah & Fry, Laura & Vaikunthanathan, Trishan & Lechler, Robert & Lombardi, Giovanna. (2018). Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Frontiers in Immunology. 9. 10.3389/fimmu.2018.00354.Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol. 2021 PMID: 34343613 https://doi.org/10.1016/j.jhep.2021.07.027Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol. 2021 PMID: 34343613 https://doi.org/10.1016/j.jhep.2021.07.027Герасимова О.А., Боровик В.В., Марченко Н.В., Тилеубергенов И.И. Толерантность и минимизация иммуносупрессивной терапии после трансплантации печени. Вестник трансплантологии и искусственных органов. 2021;23(3):162-170. https://doi.org/10.15825/1995-1191-2021-3-162-170Gerasimova O.A., Borovik V.V., Marchenko N.V., Tileubergenov I.I. Tolerance and minimization of immunosuppressive therapy after liver transplantation. Bulletin of Transplantology and artificial organs. 2021;23(3):162-170. (In Russ). https://doi.org/10.15825/1995-1191-2021-3-162-170Ronca V, Wootton G, Milani C, Cain O. The immunological basis of liver allograft rejection. Front Immunol. 2020 Sep 2;11:2155.Ronca V, Wootton G, Milani C, Cain O. The immunological basis of liver allograft rejection. Front Immunol. 2020 Sep 2;11:2155.Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar;12: 694–705.Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar;12: 694–705.Rodríguez-Pera'lvarez M, Germani G, Darius T, Lerut J,Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012 Oct;12:2797–2814.Rodríguez-Pera'lvarez M, Germani G, Darius T, Lerut J,Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic re- view and meta-analysis. Am J Transplant. 2012 Oct;12:2797– 2814.Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transplant. 2003 May 1;9:463–468.Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transplant. 2003 May 1;9:463–468.Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant. 2008;22:502–507.Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant. 2008;22:502–507.Gama JFG, Cardoso LMDF, Bisaggio RDC, Lagrota-Candido J, Henriques-Pons A, Alves LA. Immunological Tolerance in Liver Transplant Recipients: Putative Involvement of Neuroendocrine-Immune Interactions. Cells. 2022 Jul 29;11(15):2327. https://doi.org/10.3390/cells11152327. PMID: 35954171; PMCID: PMC9367574.Gama JFG, Cardoso LMDF, Bisaggio RDC, Lagrota-Candido J, Henriques-Pons A, Alves LA. Immunological Tolerance in Liver Transplant Recipients: Putative Involvement of Neuroendocrine-Immune Interactions. Cells. 2022 Jul 29;11(15):2327. https://doi.org/10.3390/cells11152327. PMID: 35954171; PMCID: PMC9367574.Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel). 2021 Mar 31;13(7):1617. https://doi.org/10.3390/cancers13071617. PMID: 33807392; PMCID: PMC8037838.Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel). 2021 Mar 31;13(7):1617. https://doi.org/10.3390/cancers13071617. PMID: 33807392; PMCID: PMC8037838.Rodríguez-Pera'lvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013 Dec 1;59:1193–1199.Rodríguez-Pera'lvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013 Dec 1;59:1193–1199.Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992 Jun;21(6 suppl 3):16–22.Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H. Mecha- nisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992 Jun;21(6 suppl 3):16–22.Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014 845438.Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014 845438.Kirk AD. Induction immunosuppression. Transplantation. 2006 Sep 15;82:593.Kirk AD. Induction immunosuppression. Transplantation. 2006 Sep 15;82:593.Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001 May;7:442–450.Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double- blind comparative study of mycophenolate mofetil and azathio- prine in combination with cyclosporine and corticosteroids in pri- mary liver transplant recipients. Liver Transpl. 2001 May;7:442– 450.Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010 Feb;23:155–168.Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010 Feb;23:155–168.Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb;148:484–486.Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treat- ment for chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb;148:484–486.Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 2017 Dec;7:358–366.Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 2017 Dec;7:358–366.Donnelly JP, Locke JE, MacLennan PA, et al. Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis. Clin Infect Dis. 2016 Jul 15;63:186–194.Donnelly JP, Locke JE, MacLennan PA, et al. Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis. Clin Infect Dis. 2016 Jul 15;63:186–194.Shepshelovich D, Tau N, Green H, et al. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey. Transpl Infect Dis. 2019 Oct;21.Shepshelovich D, Tau N, Green H, et al. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey. Transpl Infect Dis. 2019 Oct;21.

The authors declare that there are no conflicts of interest present.